Nicole Lamanna

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S2 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.

Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S5 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Supplementary Figures S1-S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S4 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S8 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies

Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies